Skip to main content
Top
Published in: Drug Safety 1/2013

01-01-2013 | Original Research Article

Key Elements in Adverse Drug Interaction Safety Signals

An Assessment of Individual Case Safety Reports

Authors: Johanna Strandell, G. Niklas Norén, Staffan Hägg

Published in: Drug Safety | Issue 1/2013

Login to get access

Abstract

Background

A large proportion of potential drug interactions are known from pre-authorization studies, but adverse drug reactions (ADRs) due to interactions (adverse drug interactions) are often first detected through astute observation in clinical practice. Individual case safety reports (ICSRs) are collected from broad patient populations and allow for the identification of groups of similar reports. Systematic screening for adverse drug interactions in ICSRs will require an understanding of which information on these reports can be suggestive of adverse drug interactions.

Objective

The aim of the study was to identify what reported information may support the identification of drug interaction safety signals in collections of ICSRs.

Methods

Three previously published safety signals of suspected adverse drug interactions were re-evaluated. To this end, 137 reports related to these signals were retrieved from the WHO Global ICSR Database, VigiBase™, and corresponding original reports were obtained from national pharmacovigilance centres. Criteria from an operational score for causality analysis of drug interactions of clinical cases, the Drug Interaction Probability Scale (DIPS), were applied to each of these reports with the aim of identifying what supportive information tends to be available in ICSRs. For three DIPS elements (plausible time course, resolution of the ADR after terminating the drug inducing the interaction without changes in affected drug therapy (positive dechallenge) and alternative causes of the reaction) we also compared the amount of information in VigiBase™ and in original reports, and in free text and structured data.

Results

Commonly fulfilled DIPS elements on reports supporting an adverse drug interaction signal were plausible time course (50 reports; 36 %) and positive dechallenge (8 reports; 6 %). Alternative causes for the observed adverse reaction were observed in 72 (53 %) reports. We found limited differences between VigiBase™ and original reports for the structured data, although a substantial amount of additional information was available in free text in original reports.

Conclusions

Information on plausible time courses and resolution of the adverse reaction upon withdrawal of the drug suspected to have induced the interaction may be a useful element in identifying suspected adverse drug interactions from ICSRs. Of these, plausible time course is by far the most commonly reported element in the three signals studied here. Our analysis also demonstrated the importance of sharing and analysing information available in free text where relevant clinical details are often available, such as those mentioned above, along with severity and dosage changes.
Literature
1.
go back to reference Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.PubMedCrossRef
2.
go back to reference Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf. 2002;11(1):65–72.PubMedCrossRef Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf. 2002;11(1):65–72.PubMedCrossRef
3.
go back to reference Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ. 2000;320(7241):1036.PubMedCrossRef Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ. 2000;320(7241):1036.PubMedCrossRef
4.
go back to reference Schneeweiss S, Hasford J, Gottler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285–91.PubMedCrossRef Schneeweiss S, Hasford J, Gottler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285–91.PubMedCrossRef
5.
go back to reference Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.PubMedCrossRef Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.PubMedCrossRef
6.
go back to reference Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.PubMedCrossRef Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.PubMedCrossRef
7.
go back to reference Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667–75.PubMedCrossRef Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667–75.PubMedCrossRef
8.
go back to reference Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674–80.PubMedCrossRef Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674–80.PubMedCrossRef
9.
go back to reference Strandell J, Caster O, Bate A, et al. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34(3):253–66.PubMedCrossRef Strandell J, Caster O, Bate A, et al. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34(3):253–66.PubMedCrossRef
10.
go back to reference Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409–19. Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409–19.
11.
go back to reference Edwards IR, Olsson S. The WHO international drug monitoring programme. In: Aronson JK, editor. Side effects of drugs annual 25. Amsterdam: Elsevier Science B.V.; 2002. p. 589–598. Edwards IR, Olsson S. The WHO international drug monitoring programme. In: Aronson JK, editor. Side effects of drugs annual 25. Amsterdam: Elsevier Science B.V.; 2002. p. 589–598.
12.
go back to reference Yue QY, Strandell J, Myrberg O. Concomitant use of glucosamine potentiates the effect of warfarin (abstract). Drug Saf. 2006;29(10):934.CrossRef Yue QY, Strandell J, Myrberg O. Concomitant use of glucosamine potentiates the effect of warfarin (abstract). Drug Saf. 2006;29(10):934.CrossRef
13.
go back to reference Strandell J, Bate A, Hägg S, et al. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009;68(3):427–34.PubMedCrossRef Strandell J, Bate A, Hägg S, et al. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009;68(3):427–34.PubMedCrossRef
17.
go back to reference Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRef Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRef
18.
go back to reference Strandell J, Bate A, Lindquist M, et al. Database SFINX. Drug-drug interactions: a preventable patient safety issue? Br J Clin Pharmacol. 2008;65(1):144–6.PubMedCrossRef Strandell J, Bate A, Lindquist M, et al. Database SFINX. Drug-drug interactions: a preventable patient safety issue? Br J Clin Pharmacol. 2008;65(1):144–6.PubMedCrossRef
19.
go back to reference Pariente A, Grégoire F, Fourrier-Réglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891–8.PubMedCrossRef Pariente A, Grégoire F, Fourrier-Réglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891–8.PubMedCrossRef
20.
go back to reference Uppsala Monitoring Centre. Azithromycin and HMG-CoA reductase inhibitors: rhabdomyolysis. WHO Signal (restricted document). 2008. p. 4–7. Uppsala Monitoring Centre. Azithromycin and HMG-CoA reductase inhibitors: rhabdomyolysis. WHO Signal (restricted document). 2008. p. 4–7.
Metadata
Title
Key Elements in Adverse Drug Interaction Safety Signals
An Assessment of Individual Case Safety Reports
Authors
Johanna Strandell
G. Niklas Norén
Staffan Hägg
Publication date
01-01-2013
Publisher
Springer International Publishing AG
Published in
Drug Safety / Issue 1/2013
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-012-0003-9

Other articles of this Issue 1/2013

Drug Safety 1/2013 Go to the issue